PDS Biotechnology (PDSB) Capital Expenditures (2014 - 2024)

PDS Biotechnology's (PDSB) quarterly Capital Expenditures came in at $1.0 in Q3 2024, down 100.0% on a QoQ basis from $170637.0 in Q4 2017.

PDS Biotechnology (PDSB) Capital Expenditures (2014 - 2024) Analysis & Trends

PDS Biotechnology (PDSB) has 5 years of Capital Expenditures data on file, last reported at $1.0 in Q3 2024.

Quarterly Capital Expenditures changed N/A year-over-year to $1.0 in Q3 2024, while the trailing twelve-month figure through Dec 2025 was $1.0 (changed 0.0% YoY) and the FY2024 annual result came in at $29000.0, changed N/A from the prior year.
Capital Expenditures slipped to $1.0 in Q3 2024, from $170637.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $1.0 in Q3 2024 to a low of $1.0 in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	34.68 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-73.57 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	6.26 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	251.02 Mn
10	PDS Biotechnology	12.02 Mn	12.02 Mn	-	-

Download Data